课题基金 / 基金详情

SURGICAL DEBULKING OF PITUITARY ADENOMAS & RESPONSIVENESS TO OCTREOTIDE LAR

SURGICAL DEBULKING OF PITUITARY ADENOMAS & RESPONSIVENESS TO OCTREOTIDE LAR
垂体腺瘤手术切除
批准号:
7376572
负责人:
WILLIAM F CHANDLER
金额:
$0.97万
依托单位国家:
美国
项目类别:
财政年份:
2006
资助国家:
美国
项目状态:
已结题
起止时间:
2006-04-05 至 2007-02-28

项目摘要

项目成果

WILLIAM F CHANDLER的其他基金

相似基金

相关文献

中文摘要
翻译
本子项目是利用由NIH/NCRR资助的中心赠款提供的资源的众多研究子项目之一。子项目和研究者(PI)可能已经从另一个NIH来源获得了主要资金,因此可以在其他CRISP条目中表示。列出的机构是中心的,不一定是研究者的机构。肢端肥大症是一种罕见但使人衰弱的疾病,由垂体肿瘤引起。目前的治疗方法非常有限。该方案比较了单独的药物治疗和手术后的药物治疗,以确定哪种方法最好地控制IGF-1,这是疾病活动的关键指标。诊断为肢端肥大症的成人受试者计划接受垂体腺瘤减容手术可能符合条件。受试者将被随机分为两组。随机的意思是偶然的,就像抛硬币一样。第一组将推迟计划手术3个月,并在此期间接受fda批准的药物Sandostatin LAR的治疗。第二组将立即接受手术。那些在手术后仍有疾病活动的患者将接受三个月的山多他汀LAR药物治疗。山多他汀LAR(也称为奥曲肽LAR)是美国食品和药物管理局(FDA)批准的一种药物。它与生长抑素相似,但比生长抑素更有效,生长抑素是一种自然产生的激素,可以抑制脑垂体释放生长激素(GH)。这项研究是为了发现手术是否能帮助山多司他汀发挥作用,以改善肢端肥大症患者的治疗选择。研究程序包括MRI、EKG、OGTT、抽血、体格检查和患者评估以评估疾病活动性。用于确定垂体手术是否改善对Sandostatin LAR的反应的主要措施是IGF-1水平,这种物质是肢端肥大症疾病活动的重要指标。
英文摘要
This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Acromegaly is a rare but debilitating disease caused by a pituitary tumor. Current therapeutic options are extremely limited. This protocol compares medical treatment alone to surgery followed by medical treatment to determine which method best controls IGF-1, a key indicator of disease activity. Adult subjects with a diagnosis of acromegaly who are scheduled to receive pituitary adenoma debulking surgery may be eligible. Subjects will be randomized into one of two arms. Randomly means by chance, like flipping a coin. The first group will delay scheduled surgery for 3 months and receive medical treatment with FDA-approved medication Sandostatin LAR during that time. The second group will receive surgery immediately. Those who continue to show disease activity after surgery will then receive medical treatment with Sandostatin LAR for three months. Sandostatin LAR (also called Octreotide LAR) is a medication approved by the Food and Drug Administration (FDA). It is similar to, but more effective than somatostatin, which is a naturally occurring hormone that inhibits the release of growth hormone (GH) from the pituitary gland. This study is being done to find out if surgery helps Sandostatin work, to improve treatment options for people with acromegaly. Study procedures include MRI, EKG, OGTT, blood draws, physical examination, and patient assessments to evaluate disease activity. The primary measure used to determine whether pituitary surgery improves the response to Sandostatin LAR is levels of IGF-1, a substance that is an important indicator of acromegaly disease activity.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
SURGICAL DEBULKING OF PITUITARY ADENOMAS & RESPONSIVENESS TO OCTREOTIDE LAR
SURGICAL DEBULKING OF PITUITARY ADENOMAS & RESPONSIVENESS TO OCTREOTIDE LAR
国内基金
海外基金
基于Akt/mTORC1信号通路研究somatostatin-14对高脂日粮下黄鳝脂肪代谢的调控机制
  • 批准号:
    32160869
  • 项目类别:
    地区科学基金项目
  • 资助金额:
    34万元
  • 批准年份:
    2021
  • 负责人:
    张亚洲
  • 依托单位:
海马CA1区Somatostatin中间神经元活性恢复延迟介导全麻后记忆损害的机制探究
Somatostatin、Cortistatin及其多个受体(SSTR)在家鸡垂体中的作用机理初步研究
  • 批准号:
    31271325
  • 项目类别:
    面上项目
  • 资助金额:
    80.0万元
  • 批准年份:
    2012
  • 负责人:
    王亚军
  • 依托单位:
激活肿瘤微环境中somatostatin-MAPK途径抑制晚期前列腺癌进展
  • 批准号:
    81172435
  • 项目类别:
    面上项目
  • 资助金额:
    60.0万元
  • 批准年份:
    2011
  • 负责人:
    刘照旭
  • 依托单位: